BNET Industries
Last Fiscal Year Sales:$500.0M
- Private
- IN
Dow Jones Description
Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. The Company is ranked amongst the top ten global generic companies and has a presence in 23 of the top 25 pharma markets of the world. The Company with a global footprint in 49 countries, worldclass manufacturing facilities in 11 and a diverse product portfolio, is rapidly moving towards global leadership, riding on its success in the world's emerging and developed markets.
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
INDIA'S RANBAXY RECALLS DRUGS FOR SKIN DISEASE FROM US MARKET
-
Nuvo Research Dimethaid Research signs license agreement with Ranbaxy Laboratories
-
Nuvo research provides WF10 licensing and development update
-
Ranbaxy: FDA Issues Will Take Long Time to Resolve
-
Nomura rates Ranbaxy 'Reduce'; target Rs 261
-
Ranbaxy signs in-licensing agreement with Medy-Tox
-
Ranbaxy signs licence deal with S Korean firm
-
Ranbaxy Launches Authorized Generic Version of Rocaltrol
-
INDIA'S RANBAXY PARTNERS WITH VALIDUS TO SELL CALCIUM DRUG IN US
-
Ranbaxy launches generic Rocaltrol
-
Dainippon Agrees to Buy Sepracor
-
Ranbaxy Profit Soars
-
Medicis sues Ranbaxy over generic
News & Analysis
Filter by
ranbaxy laboratories ltd. - All News and Analysis
Ranbaxy suffers 53% fall in US sales
Financial Times
- 2009-10-26
The financial pain inflicted by a US import ban on some of the products of Ranbaxy Laboratories, India's largest drugsmaker, continues to hurt the company a year after it was first imposed.In the US, sales fell 53 per cent to $44m during the quarter to the end of September...
A Ranbaxy Bid Would Smell Like Desperation on Pfizer
BNET
- 2008-06-16
Last last week, reports out of India suggested that Pfizer might make a hostile bid for generic-drug maker Ranbaxy Laboratories, which last week agreed to sell itself to Japan's Daiichi Sankyo for roughly $4 billion. Pfizer may or may not actually try to bust up the Daiichi-Ranbaxy...
Japanese Pharma Waves Its Charge Card
BNET
- 2008-06-12
Japanese drugmakers are anxious to expand their presence in global pharma/biotech markets where they've long been largely shut out -- and the strong yen is making it cheaper for them to basically buy their way in. Interestingly enough, some of these deals are bypassing the U.S. altogether. ...
Research and Markets: Gain Insight in to Ranbaxy Laboratories Limited
- 2007-12-13
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c77390) has announced the addition of "Company Analysis - Ranbaxy Laboratories Limited" to their offering.
Ranbaxy gets US nod to mkt its drug.
- 2007-02-01
Feb. 1--NEW DELHI -- Gurgaon-based pharmaceutical major Ranbaxy Labs today announced that RLL has received approval from the US Food and Drug Administration to market Amoxicillin and Clavulanate Potassium for Oral Suspension. The Division of Bioequivalence has determined the Ranbaxy formulation to be bioequivalent and, therefore,...
They're parking their tractors on our lawns
- 2006-07-23
Like other rural residents of Southern Mississippi, Jamie Lucenberg faced a huge cleanup job in the wake of Hurricane Katrina. He needed a tractor to clear debris and trees from his 17-acre family farm, 16 miles north of devastated Biloxi. "We literally had to cut our way up and down...
Research and Markets: View a Detailed Listing of All Ranbaxy Laboratories Deals and Alliances Announced between January 2001 and March 2006
- 2006-06-23
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c38645) has announced the addition of "Ranbaxy Laboratories Limited Deals Briefing" to their offering.
Ariba and IIMM Announce Sourcing Excellence Awards; Ranbaxy Laboratories, Tata Steel and Hindustan Motors Take Top Honors
- 2006-02-28
NEW DELHI, India -- AribaR, Inc. (Nasdaq:ARBA), the leading spend management solutions provider, and the Indian Institute of Material Management IIMM, today announced the recipients of the IIMM-Ariba Sourcing Excellence Awards. Designed to recognize distinctive sourcing and supply chain leadership and significant contributions towards this practice, the awards were given...
Lipitor creator Roger Newton and Pfizer have faced down a challenge to their patent, but still fight their own Drug war.
- 2005-12-19
Byline: Andrew Dietderich For the two decades of blood, sweat, tears, late nights and lean years that went into developing the world's biggest selling drug, Roger Newton isn't about to hand it over to someone else. And he especially isn't about ...
Ranbaxy to Appeal U.S. District Court Decision Upholding Pfizer Atorvastatin Patents.
- 2005-12-17
PRINCETON, New Jersey, December 17 /PRNewswire/ -- Ranbaxy Laboratories Limited announced today that the U.S. District Court of Delaware ruled against Ranbaxy in its case for non-infringement and invalidation of two Pfizer patents on atorvastatin. Atorvastatin is a cholesterol-lowering drug, marketed by...
Those who viewed this also viewed...
Industry Transcripts by Seeking Alpha
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
-
Arena Pharmaceuticals Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ARNA
Glass Door
Ranbaxy
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
